Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 5;11(7):2030. doi: 10.3390/jcm11072030

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of combination treatment with S. aureus EVs and tamoxifen in breast cancer cells. (A) EVs derived from S. aureus (indicated by a red arrow) were confirmed by transmission electron microscopy. (B) The average diameter of S. aureus EVs was obtained using dynamic light scattering size distribution. (C) The bar chart shows the percentage of viable MCF7 cells after treatment with S. aureus EVs and/or tamoxifen. (D) Relative BT474 cell survival percentages after treatment with S. aureus EVs and/or tamoxifen. This experiment was repeated three times. (E) Protein expression of p−AKT, p53, p−ERK, and p21 was detected by Western blotting after tamoxifen and/or S. aureus EVs treatment. lane 1, control; lane 2, S. aureus EVs 100 ng/mL; lane 3, 10 μM tamoxifen; lane 4, 10 μM tamoxifen plus S. aureus EVs 100 ng/mL. (F) The mRNA expression of cyclins, cyclin−dependent kinase inhibitors, and TNF−α was confirmed by qRT−PCR. CCND1, cyclin D1; CCNE2, cyclin E2; CCNA2, cyclin A2; CCNB1, cyclin B1, CDKN1A:p21, and CDKN1B:p27; TNF−α, tumor necrosis factor−α. *** p < 0.001.